Hair Growth-Promoting Effects of a Multi-Targeted Cosmetic Formulation Containing PYGL, DP2, and 15-PGDH Inhibitors Developed Using AI-Based DeepZema in Androgenetic Alopecia: A 24-Week Randomized Controlled Trial

This study evaluated the efficacy and safety of a multi-targeted cosmetic formulation, TrinogeniX™, for treating androgenetic alopecia (AGA) in a 24-week randomized controlled trial with 56 participants, 49 of whom completed the study. The formulation, developed using AI-based DeepZema®, contains inhibitors targeting glycogen phosphorylase, the prostaglandin D2 receptor, and 15-hydroxyprostaglandin dehydrogenase. Results showed a significant increase in hair density and thickness in the test group compared to the placebo group, with expert assessments and subjective evaluations supporting these findings. No adverse events or significant abnormalities were reported, indicating that the formulation is a safe and effective treatment option for AGA.